Agenus' Investigational Cancer Combo Therapy Shows 33% Durable Responses In Ovarian Cancer

Agenus Inc AGEN announced results from a cohort of 24 evaluable patients in an expansion of its Phase 1b study of botensilimab (multifunctional CTLA-4 antibody) in combination with balstilimab (PD-1 antibody) in patients with recurrent platinum-resistant/refractory ovarian cancer.
These findings showed a 33% overall response rate (ORR).
Other PD-(L)1 + CTLA-4 combinations in other trials reported 3-10% response rates in a comparable patient population.
Also Read: Agenus Presents Clinical Data Demonstrating Durable Responses For Colorectal Cancer Candidate.
The ovarian cancer cohort is part of a large study evaluating the safety, efficacy, and dose optimization of botensilimab alone and in combination with balstilimab in multiple solid tumors.
Agenus is currently enrolling in Global Phase 2 ACTIVATE trial programs in metastatic microsatellite stable colorectal cancer, melanoma, and pancreatic cancers.
Based on recent positive findings at SITC, Agenus is also expanding enrollment of its anti-PD-(L)1 relapsed/refractory non-small cell lung cancer cohort of the Phase 1b study and planning additional NSCLC studies.
The disease control rate was 67%, and the median duration of response was not reached, with a manageable tolerability profile.
Price Action: AGEN shares are up 7.05% at $1.60 on the last check Monday.

Momentum38.97

GrowthNot Available

QualityNot Available

Value31.06

Short

Medium

Long